Labeling trial drugs

All of the above trials were conducted in adults and, to the best of our knowledge, there are no trials of antipsychotic medication in children with psychoses and MR. To date there have been two double-blind trials of antipsychotic drugs in normal-IQ children and adolescents with schizophrenia, as well as several open-label trials (Ernst et al., 1999). The majority of these studies and case reports have demonstrated substantial reductions in schizophrenic symptoms. Given the lack of data on children and adolescents having both MR and schizophrenia, it seems that clinicians have little choice but to follow the standard of care applied with normal-IQ schizophrenic children, namely to use anti-... 

Novel and experimental drug treatments. A variety of alternative drug treatments have been used in OCD. Of those considered here, intravenous clomipramine is the only treatment supported by a reasonable degree of empirical evidence. Several open-label trials suggest that intravenous administration of clomipramine may be helpful in patients with OCD that is refractory to oral clomipramine (Fallon et al. 1992 Thakur et al. 1991 Warneke 1989]. 

As with other drugs, a methodologically rigorous study addressing this issue has not been done with venlafaxine. Nevertheless, there are data from an open-label trial of venlafaxine that warrant comment (149). In this study, high-dose venlafaxine produced an acute response in more than 30% of patients who had historically not adequately benefited from adequate trials of at least three antidepressants from different classes or two antidepressants plus ECT. Until more definitive data are available, this study does support a trial of high-dose venlafaxine in such patients. 

Presently, most experts recommend the SSRIs as a first-line medication for PTSD despite their troublesome adverse effects. These drugs can alleviate PTSD symptom clusters, anxiety, and depression, as well as dissociative symptoms, as shown in an open-label trial by Marshall et al. ( 276). 

In patients with chronic idiopathic thrombocytopenia (UP) who failed to respond adequately to previous treatment with steroids, immunoglobulins, or splenectomy, romiplostim significantly increased platelet count in most patients. In a 6-week placebo-controlled study in which patients were treated weekly with 1 or 3 mcg/kg, 12 of 16 patients reached the targeted platelet range of 50,000-450,000 platelets/mL. Romiplostim does not appear to decrease the rate of platelet destruction in ITP as platelet counts returned to pretreatment levels after the drug s discontinuation. An open label trial found that many patients maintained a platelet count of 100,000 platelets/mL or higher over a 48-week period and that over half of the patients were able to discontinue other therapies. Romiplostim is initiated as a weekly subcutaneous dose of 1 mcg/kg and then continued at the lowest dose required to maintain a platelet count of at least 50,000 platelets/mL. 

The key elements of an inspection are to ensure that the facility is capable of fulfilling the application commitments to manufacture, process, control, package, and label a drug product following GMP the adequacy and accuracy of analytical methods submitted, to ensure that these methods are proper for the testing proposed correlation between the manufacturing process for clinical trial material, bioavailability study material, and stability studies and submitted process that the scientific data support full-scale production procedures and controls that only factual data have been submitted and that the protocols are in place to validate the manufacturing process. 

The requirements for the format and content of the IND application, as well as the requirements governing the use of the IND, are provided in Title 21 of the Code of Federal Regulations (21 CFR), Section 312. Unlike an NDA, the FDA does not formally approve an IND submission. If the FDA reviewers believe that the proposed clinical trial(s) submitted in the IND are acceptable from a safety and risk versus benefit viewpoint, the IND is in effect, and the compound that is the subject of that IND may be shipped in interstate commerce for the purpose of conducting specific clinical trials. Drugs shipped under an IND have specific labeling requirements, and false or misleading statements, as well as any claims regarding safety and efficacy, are prohibited. 

A discrepancy between subjective improvement of spasticity versus objectively determined measurements was also noted by Ungerleider et al. who treated 13 MS patients (in a double blind, placebo controlled, cross-over study) who had serious side-effects on treatment with conventional drugs [138], With a dose of 7.5 mg zf9-THC, all patients reported a decrease in spasticity however, in objective functional tests (limb spasticity, co-ordination and weakness and reflexes) no improvement was noted. In contrast, Meinch et al. found that, on smoking marijuana in an open label trial, an MS patient showed improved mobility, reduced spasticity and tremor measured by objective methods [139],... 

Of 39 patients who had bone marrow transplants and who were randomized to receive either co-trimoxazole or atovaquone as prophylaxis in an open-label trial, eight taking co-trimoxazole withdrew because of presumed drug reactions, although in five of these the reported neutropenia and thrombocytopenia could have been a consequence of transplantation itself or of other drugs (2). None of 16 patients treated with atovaquone withdrew. This rate of reported adverse effects with co-trimoxazole is higher than usually reported in clinical practice with prophylactic dosages. 

First MR. An update on new immunosuppressive drugs undergoing preclinical and clinical trials potential applications in organ transplantation. Am J Kidney Dis 1997 29(2) 303-17. Birck R, Warnatz K, Lorenz HM, Choi M, Haubitz M, Grunke M, Peter HH, Kalden JR, Gobel U, Drexler JM, Hotta O, Nowack R, Van Der Woude FJ. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis a six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 2003 14(2) 440-7. 

Zonisamide. is a sulfonamide antiepilepsy drug with sodium and calcium channel-blocking actions. A small preliminary open label trial of zonisamide 100-600 mg daily in 15 patients with BED showed it to reduce the frequency of binge eating and lower body weight in the eight patients who completed the 12 week trial (McElroy et al. 2004). 

Alitretinoin (panretin) is a retinoid that binds ail types of retinoid receptors and is approved only for treatment of the skin manifestations of Kaposi s sarcoma. Approximately 50% of patients in an open-label trial responded positively to topical application of this drug. 

---